Shanghai Shyndec Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Yong Liu
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
We Ran A Stock Scan For Earnings Growth And Shanghai Shyndec Pharmaceutical (SHSE:600420) Passed With Ease
Mar 14
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?
Dec 12Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching
Nov 17Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth
Oct 08Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?
Aug 23Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified
May 06Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?
Apr 30Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)
Apr 05CEO
Yong Liu (55 yo)
less than a year
Tenure
Mr. Yong Liu was Vice Chairman of the Board of Shanghai Shyndec Pharmaceutical Co., Ltd. from April 28, 2021 until January 13, 2025 and serves as President and Director Since September 2024.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | 4.1yrs | no data | no data | |
| Independent Director | 2.5yrs | CN¥240.00k | no data | |
| Independent Director | 6.3yrs | CN¥240.00k | no data | |
| Chairman of the Supervisory Board | 5.5yrs | no data | no data | |
| Director | 5yrs | no data | no data | |
| Independent Director | 4.1yrs | CN¥240.00k | no data | |
| Supervisor | 2.5yrs | no data | no data | |
| Employee Supervisor | less than a year | no data | no data |
4.1yrs
Average Tenure
51.5yo
Average Age
Experienced Board: 600420's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/17 19:56 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Shyndec Pharmaceutical Co., Ltd. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| null RESEARCH DEPARTMENT | China Merchants Securities Co. Ltd. |
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |